Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
|Articles|January 2, 2019
- Pharmaceutical Technology-01-02-2019
- Volume 43
- Issue 1
Microplate Spectrophotometer
The Epoch 2 Microplate Spectrophotometer from BioTek Instruments has added features that include monochromator-based individual wavelength selection or wavelength scanning from 200–999 nm to accommodate a range of assays, including nucleic acid and protein quantification, enzyme-linked immunosorbent assay, microbial growth, endotoxin, reactive oxygen species assays, and enzyme kinetics.
Advertisement
The Epoch 2 Microplate Spectrophotometer from BioTek Instruments has added features that include monochromator-based individual wavelength selection or wavelength scanning from 200–999 nm to accommodate a range of assays, including nucleic acid and protein quantification, enzyme-linked immunosorbent assay, microbial growth, endotoxin, reactive oxygen species assays, and enzyme kinetics. New onboard software eliminates the need for a separate computer and includes predefined common protocols for rapid assay setup and recall. Custom protocol definition, storage, and selection are easily accomplished via the optional color touchscreen interface. Endpoint, kinetic, and spectral scanning applications are all available from the touchscreen; data can be output to a USB flash drive or printer.
The spectrophotometer is compatible with 6- to 384-well microplates and cuvettes as well as the company’s Take3 Micro-Volume Plate for dilution-free nucleic acid quantification in volumes as low as 2 µL. Advanced shaking profiles include linear, orbital, and double orbital, and 4-Zone incubation to 65 ºC and Condensation Control facilitate temperature-sensitive assays.
Articles in this issue
over 7 years ago
Packaging Peril: ‘No-Deal’ Brexit May Lead to Missed Deadlineover 7 years ago
Looking Beyond the Deadlineover 7 years ago
Great Expectationsalmost 8 years ago
Smarter Packaging Comes to the Pharma Marketalmost 8 years ago
Continuous Processing: Challenges and Opportunities of Virus Filtrationalmost 8 years ago
Improved Mixer Lift and Seal Designsalmost 8 years ago
Tabletop Spray Dryeralmost 8 years ago
Electrical Position Indicator for Linear Actuatorsalmost 8 years ago
FDA Marks Record Year for New Drug Approvalsalmost 8 years ago
Internal and External Challenges to Pharma in 2019Advertisement
Related to this article
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Advertisement
Advertisement